[
| E-mail
]
Contact: Joe Dangornewsbureau@mayo.edu
507-284-5005Mayo Clinic
CHICAGO Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were…
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
No comments:
Post a Comment